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Abstract
Background—The test-negative design (TND) to evaluate influenza vaccine effectiveness is 
based on patients seeking care for acute respiratory infection, with those who test positive for 
influenza as cases and the test-negatives serving as controls. This design has not been validated for 
the inpatient setting where selection bias might be different from an outpatient setting.
Methods—We derived mathematical expressions for vaccine effectiveness (VE) against 
laboratory-confirmed influenza hospitalizations and used numerical simulations to verify 
theoretical results exploring expected biases under various scenarios. We explored meaningful 
interpretations of VE estimates from inpatient TND studies.
Results—VE estimates from inpatient TND studies capture the vaccine-mediated protection of 
the source population against laboratory-confirmed influenza hospitalizations. If vaccination does 
not modify disease severity, these estimates are equivalent to VE against influenza virus infection. 
If chronic cardiopulmonary individuals are enrolled because of non-infectious exacerbation, biased 
VE estimates (too high) will result. If chronic cardiopulmonary disease status is adjusted for 
accurately, the VE estimates will be unbiased. If chronic cardiopulmonary illness cannot be 
adequately be characterized, excluding these individuals may provide unbiased VE estimates.
Conclusions—The inpatient TND offers logistic advantages and can provide valid estimates of 
influenza VE. If highly vaccinated patients with respiratory exacerbation of chronic 
cardiopulmonary conditions are eligible for study inclusion, biased VE estimates will result unless 
this group is well characterized and the analysis can adequately adjust for it. Otherwise, such 
groups of subjects should be excluded from the analysis.
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Introduction
The antigenic variability of seasonal influenza viruses requires frequent reassessments of the 
effectiveness of vaccines designed to prevent influenza infection and morbidity. However, 
randomized controlled trials are no longer ethical in settings where seasonal influenza 
vaccination is widely recommended, such as in the USA.1 The socalled ‘test-negative’ 
design (TND) has become a popular choice for post-licensure observational studies of the 
effectiveness of vaccines for influenza.2–10 Both cases and controls are identified in a 
clinical setting among patients meeting certain clinical criteria, e.g. for acute respiratory 
infection (ARI) or ‘influenza-like illness’ (ILI) and who consent to participate in the study. 
Those testing positive for influenza with a sensitive and specific assay, usually by reverse-
transcription polymerase chain reaction (RT-PCR), are designated cases and those who test 
negative for influenza are used as controls. Vaccine effectiveness (VE) is calculated as VE = 
(1- ORV) * 100%,11 where ORV is the ratio of the odds of being vaccinated in cases vs the 
odds being vaccinated in controls or, equivalently, the odds of being a case in vaccinated vs 
the odds of being a case in unvaccinated study subjects. The popularity of this design in 
ambulatory settings can be explained not only by its ease of implementation, but also by the 
implicit conditioning on healthcare-seeking practices, which eliminates an important source 
of selection bias. The general validity of VE estimates obtained from TND studies 
conducted in ambulatory settings (ambulatory TND) has recently been confirmed for a wide 
range of conditions.11–13
Recent investigations have used a TND approach to examine the effectiveness of influenza 
vaccination against influenza-related hospitalizations.14–25 VE estimates from both inpatient 
and outpatient TND studies are used as measures of VE for specific influenza seasons and 
inform public health responses. The validity of the TND in the inpatient setting (inpatient 
TND), however, has yet to be examined. In fact, some VE estimates from inpatient TND 
studies appear to exceed VEs usually encountered in ambulatory settings. For example, 
Belongia et al. estimated influenza vaccine effectiveness for all ages against influenza-
associated hospitalizations for the seasons 2006–7 in the USA to be 88% (95% confidence 
interval (CI) 13%, 100%), whereas North American ambulatory TND studies reported 
adjusted VE estimates of 52% (CI 22%, 70%)4 and 46% (CI 17%, 65%)26 for the same 
season. Similarly, Gefenaite et al.22 reported for the season 2012–13 an adjusted adult 
influenza VE of 86% (CI 19%, 97%) from an inpatient TND study in Lithuania. A European 
ambulatory TND study from the same year reported a VE of 49% (95% CI 32%, 62%).27 
This discrepancy could reflect an effect of vaccination on disease severity, i.e. vaccinated 
individuals might tend to develop less severe influenza disease if infected and thus be less 
likely to require hospitalization, or it might simply reflect the lack of precision in the 
inpatient TND VE estimates. However, it could also be the result of selection bias if 
influenza-negative controls are substantially different from the source population in their 
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uptake of influenza vaccination. For instance, subjects suffering from chronic conditions 
such as congestive heart failure or chronic obstructive pulmonary disease (COPD) (CP 
individuals) are more likely to be hospitalized with non-infectious respiratory disease (e.g., 
decompensation of their heart condition or COPD exacerbation). If they are also more likely 
to be vaccinated than the source population from which the cases are drawn, selection bias 
would result.28
Here, we first examine the interpretation of VE estimates obtained from inpatient TND 
studies: does VE represent the level of protection against influenza hospitalizations? We 
then examine the effect on VE estimates of enrolling CP individuals for respiratory non-ARI 
exacerbation. We also investigate the effect of accurate and inaccurate adjustment for CP 
status on VE estimates. We theoretically derive the mathematical quantities of interest and 
use a simulator to verify the theoretical results.
Methods
Assumptions
We make use of notation previously described.11 Parameters with their symbols and baseline 
values are shown in Table 1. We assume that the incidence of influenza ARI and ARI of 
other aetiologies (‘non-influenza’) is driven by incidence rates λI(t) and λNI(t), respectively, 
where t represents time in days. We assume that influenza viruses represent one antigenic 
entity such that infection with the virus results in full immunity to influenza viruses for the 
remainder of the study. ARI of non-influenza aetiology does not change the future risk of 
acquiring ARI of any aetiology (influenza, non-influenza). Study inclusion criteria are broad 
enough to allow for the enrolment of subjects admitted to inpatient care for respiratory 
exacerbation of underlying chronic medical conditions, such as COPD, asthma or congestive 
heart failure, hence referred to as CP conditions. To differentiate such events from ARI-
related events we will use the term non-ARI events. Individuals suffering from CP 
conditions are also assumed to have a higher vaccination uptake than the remainder of the 
population. All subjects are susceptible to influenza infection before influenza vaccination or 
natural infection with influenza virus. Influenza vaccination is completed before the 
beginning of the study period. VE is the same for CP and non-CP subjects and an ‘all-or-
none’ model of the vaccination effect is assumed according to which a proportion φ (=VE) 
of those susceptible to influenza who were vaccinated become fully immune to influenza 
infection (vaccination-mediated); accordingly, influenza vaccination fails to protect a 
proportion 1 − φ against influenza virus infection (vaccine failure). Despite vaccine failure, 
an individual’s probability of becoming hospitalized with influenza may be reduced by the 
factor (1 − ι) (Greek letter iota). This represents a mitigating effect of influenza vaccination 
on influenza disease severity. Influenza vaccination does not directly modify the probability 
of non-influenza outcomes. CP subjects are at higher risk for non-ARI events than non-CP 
subjects (λCP1(t) and λCP0(t), respectively). Given an ARI or non-ARI event, subjects are 
hospitalized with a given probability which depends on the type of event and on their CP 
status: For example, γNI1 is the probability of a CP subject being hospitalized with non-
influenza ARI; see Table 1. All subjects hospitalized with an ARI or non-ARI event are 
tested for influenza and included in the study with probability σ. The laboratory test used to 
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assess influenza infection has perfect accuracy. Similarly, both vaccination and CP status (0 
or 1) are assessed accurately. We assume that CP status is adjusted for in the analysis by the 
use of a binary covariate in the logistic regression analysis. For the sake of simplicity we 
ignored confounders of practical importance such as age and calendar time.
Simulation study
We simulated the daily incidence of the events of interest (influenza and non-influenza ARI, 
non-ARI events), the occurrence of relevant downstream events (hospitalization, influenza 
testing, study participation etc.) which resulted in simulated data sets that were analysed 
using logistic regression analysis. This allowed us to investigate the effect of certain 
parameters on resulting VE estimates (Supplement 2, available as Supplementary data at IJE 
online). We did not model transmission, but based the daily incidence on given incidence 
rate functions for all events (see below). Briefly, the population is subdivided into non-CP 
(‘normal’), and CP subjects, who can be either vaccinated or unvaccinated. Infections with 
influenza virus, with non-influenza ARI agents and non-ARI events were generated for each 
day of the simulation by applying the respective incidence rates to the respective population 
groups. Driven by values of the parameters that represent conditional probabilities, such as 
the probability of non-CP subjects being hospitalized given influenza infection (e.g. γI0), 
data generation from an inpatient TND study is simulated. To assess the ‘meaning’ of VE 
estimates from inpatient TND studies, hypothetical cohort studies, representing the whole 
population, were simulated in which inpatient TND studies were nested. We then varied ι to 
produce a specific VE against hospitalization:
φ* = 1 − (1 − ι) (1 − φ) (see Supplement 1 S9 available as Supplementary data at IJE online) 
and estimated φ* as
where RR is the relative risk of influenza hospitalization in those vaccinated compared with 
those not vaccinated, estimated by CP-adjusted binomial regression and exponentiating the 
coefficient estimate associated with vaccination. For each simulated TND study we 
estimated VE using logistic regression analysis, adjusting for CP status. We then compared 
the inpatient TND VE estimates with the cohort values in 10 000 simulations for each φ*.
To investigate the effect of CP status on VE estimates from inpatient TND studies, we 
simulated 10 000 studies, for each calculating the crude VE, VE by CP status (separate 
analysis for CP and non-CP subjects) and adjusted VE using logistic regression analysis 
(Supplement 1). We also simulated the situation where CP subjects were not homogeneous 
with respect to their vaccination uptake and risk of non-ARI events, such that their marginal 
vaccination uptake and non-ARI risk remained the same (80% and 4 per 1000 per day, 
respectively), but two-thirds of them suffered 5-fold higher rates of non-ARI events 
compared with non-CP subjects and one-third suffered 20-fold higher rates of non-ARI 
events than non-CP subjects. Of the former group 75% were vaccinated, whereas 90% were 
vaccinated of the latter group.
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The simulation model was implemented using R 3.1.129 and can be downloaded 
(Supplement 2). All simulations were based on fixed sets of parameters (Table 1) unless 
explicitly stated. The bias was calculated as the median difference between the estimated VE 
and φ, along with the 2.5th and 97.5th percentiles of that difference as empirical 95% 
confidence intervals (CI).
Results
The interpretation of VE estimates from inpatient TND studies
Theoretically, if the controls are representative of the source population with regard to 
vaccine receipt, if both outcome and vaccination status are accurately measured and if the 
vaccine provides ‘all-or-none’ protection, VE estimates from inpatient TND studies should 
represent unbiased estimates of the true VE against laboratory-confirmed influenza 
hospitalization for the general population (Supplement 1, equation S9). This was confirmed 
by simulation where the VE estimates based in inpatient studies were highly consistent with 
the actual protection from influenza hospitalization in the population cohort (Table 2, 
columns 2–4) even though they are derived from hospitalized subjects only. If, in addition, 
vaccination does not modify influenza disease severity (ι = 0), VE against hospitalization 
equals VE against influenza virus infection (Supplement 1, S10, Table 2, first row). Given 
VE against infection (φ), VE against laboratory-confirmed influenza hospitalization, φ*, 
increases linearly with the ‘attenuation factor’ ι because φ* = 1 − (1 − ι) (1 − φ). This was 
confirmed by simulation (Table 2). The difference between VE against infection (φ) and the 
VE against laboratory-confirmed influenza hospitalization (φ*), given a certain ‘attenuation 
factor’ ι, is larger for smaller values of φ than it is for larger values (Supplement 1, S9). As 
only outcomes that test positive for influenza, usually by molecular methods such as RT-
PCR, define case status, hospitalizations due to late complications of influenza will not be 
captured and the VE estimated in inpatient TND studies relates only to hospitalization with 
laboratory-confirmed influenza and not necessarily to all influenza-associated 
hospitalizations.
Bias in VE estimate from an inpatient TND
If CP status is associated both with high vaccine uptake and with the risk of non-ARI events, 
and if such events are eligible for study inclusion, VE estimates that are not adjusted for the 
CP status (‘crude’) will be biased. This bias can be classified as selection bias because 
highly vaccinated controls are selectively included in the study, which leads to a 
misrepresentation of the source population in terms of vaccination prevalence, biasing VE 
estimates towards falsely high values (Table 3 and Supplement 1). The magnitude of the bias 
depends on the assumptions regarding the incidence of non-ARI events in both non-CP and 
CP individuals, as well as the vaccination coverage in both groups. If vaccination coverage 
does not depend on CP status, then unbiased estimates result without CP-adjustment 
(Supplement 1; simulation results not shown). CP-adjusted VE estimates were sensitive to 
parameters that drive the accuracy of the influenza test, as well as assessment of vaccination 
and CP status (Supplement 1). If CP status is either adjusted for accurately or VE is 
estimated separately for CP and non-CP individuals, unbiased estimates will result (Table 3 
and Supplement 1).
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Bias in VE estimates from inpatient TND with heterogeneity in CP status
If CP status is not a binary characteristic, but CP individuals rather fall into two or more 
categories defined by vaccination uptake and study inclusion probabilities (controls), and if 
that heterogeneity is not fully characterized, adjustment for CP status will not result in full 
removal of the bias (Table 3). This scenario mimics a situation in which CP status cannot be 
fully characterized. Similarly, stratification on the imperfect binary CP indicator will result 
in a biased VE estimated among CP individuals (restricted analysis) (Table 3). However, as 
long as non-CP subjects (CP = 0) are homogeneous with respect to vaccination uptake and 
probability of being included in the study as controls, the analysis restricted to non CP 
subjects will give rise to unbiased VE estimates (Table 3).
Discussion
We demonstrated that, under certain general assumptions, VE estimates from inpatient TND 
studies can be interpreted as the level of protection bestowed by influenza vaccination 
against hospitalization with laboratory-confirmed influenza for the source population, 
despite the fact that the study is conducted only among inpatients. If vaccination does not 
mitigate disease severity in break-through influenza infections, then VE estimates from 
inpatient TND studies also quantify protection from influenza virus infection. Because proof 
of active infection with influenza virus is required for the case definition, late complications 
of influenza leading to hospitalization are not captured by inpatient TND study-derived VE 
estimates. Such test-negative VE estimates may thus underestimate the level of protection 
from complications of influenza infection.
The TND offers logistical advantages over other study designs since all enrolled patients are 
utilized either as cases or controls. Even though the methodological issues faced by inpatient 
TND studies do not fundamentally differ from the issues encountered by TND studies 
conducted in ambulatory patients, there are important practical differences: In studies of 
ambulatory patients seeking care for non-life-threatening ARI, the choice by individuals to 
visit a healthcare provider is a sine qua non for study inclusion. The TND implicitly corrects 
for the selection bias associated with healthcare-seeking behaviour11–13 which is, besides its 
practical advantages, the main benefit of the ambulatory TND. In the inpatient setting, 
access to care may introduce selection bias that could be avoided by conditioning on hospital 
admission.
We did, however, identify a potential source of selection bias that could affect VE estimates 
from inpatient TND studies. Certain chronic conditions, here referred to as CP conditions, 
that may be associated with high vaccination coverage may also cause inpatient admission of 
subjects for non-ARI events, e.g. respiratory exacerbation of their underlying condition that 
are not associated with influenza infection. If these events meet the study inclusion criteria, 
these subjects would be enrolled as controls. There, in fact, is indirect evidence for the over-
representation of CP subjects among controls in some inpatient TND. For example, cases 
and controls may differ in indicators of chronic illness that are predictive both of vaccination 
status and of the probability to be hospitalized with respiratory non-ARI events. In several 
inpatient VE studies,18,23,24,30,31 controls were older than cases and much more likely to 
suffer from heart disease and pulmonary disease, as well as other conditions which, 
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conceivably, might have increased their vaccination coverage and their probability of being 
admitted for inpatient care for non-ARI events and of thus of being enrolled in the study as 
controls.
We have shown, both by theoretical considerations and by simulation that, if these 
conditions (CP conditions) are adequately adjusted for or if the analysis is restricted to non-
CP conditions and if both influenza infection and vaccination status are assessed with a high 
level of accuracy, unbiased VE estimates can be obtained from inpatient TND studies even if 
subjects are enrolled in the study because of non-ARI events. In reality, however, adjustment 
for CP status may not be straightforward. If, for example, “CP subjects” are heterogeneous 
with respect to their risk for non-ARI events that may lead to study inclusion and with 
respect to their vaccination uptake, inaccurate adjustment by CP status will result in biased 
VE estimates. This problem of inaccurate adjustment of selection bias is well known, for 
example, in educational research.32 A sensitivity analysis comparing full VE estimates with 
VE estimates obtained from the data restricted to not chronically ill patients might indicate a 
problem with selection bias if the two estimates are substantially different. In that case, the 
restricted estimate should be reported. It is important to note that we have focused our 
analysis on a scenario which is more representative of inpatient TND studies in adults rather 
paediatric populations which may offer quite different challenges.33
Our analysis of the inpatient TND has some limitations. First, we assumed perfect accuracy 
in the assessment of both influenza and vaccination status. Jackson et al.34 recently showed 
that, although misclassification of influenza status tended to result in a slightly greater bias 
of VE estimates in TND studies compared with other designs, the magnitude of the bias was 
trivial under realistic assumptions regarding VE, the accuracy of RT-PCR and influenza 
attack rates. The difficulty in detecting late complications of influenza infection can also be 
construed as a problem of sensitivity. Even though the impact of inaccurate assessment of 
vaccination status is less understood, the potential effect of inaccurate characterization of 
vaccination status on VE estimates is concerning, although not specific for inpatient TND 
studies. It has been shown that vaccination self-reports may be unreliable, often leading to 
underreporting of influenza vaccination,35–37 but occasionally to over-reporting.38 On the 
other hand, neither medical records nor vaccine registries are likely perfect sources for 
vaccination status.39 Misclassification of vaccination status could have unpredictable 
consequences for the resulting VE estimates. Our sensitivity analysis (Supplement 1) 
confirms that misclassification of case-control, vaccination or CP status is a source for 
concern. Second, we assumed an ‘all-or-none’ vaccination effect model, according to which 
vaccination either results in full immunity or full susceptibility to infection. As we have 
shown previously,11 odds ratio-derived VE estimates are biased toward 0 if vaccination 
reduces the instantaneous risk by a given fraction (VE) instead, a mechanism referred to as 
‘leaky vaccine’ model.40 Third, our quantitative evaluation of biases in VE estimates is 
based on assumptions about the incidence of influenza infection, non-influenza ARI and 
non-ARI events, as well as assumptions about hospitalization probabilities and, importantly, 
the prevalence of underlying medical conditions that are associated with both vaccination 
coverage and the likelihood of study inclusion as controls (CP status). These parameters are 
highly context-dependent and can be chosen to produce both trivial and massive biases of 
VE estimates not adjusted for CP. Finally, we assumed influenza virus to represent a single 
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antigenic entity. This assumption clearly does not capture the antigenic and immunological 
complexity of questions regarding vaccine effectiveness that arise from the interaction 
between sequential natural exposure and vaccination responses.41,42. More refined models of 
influenza circulation and of immunological mechanisms involved in the effect of influenza 
vaccination may reveal different sources of biases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Test-negative design (TND) studies of influenza vaccine effectiveness (VE) 
are increasingly used with inpatients
• In the absence of bias, VE estimates from inpatient TND studies represent the 
protection of the source population from hospitalization with influenza
• Late complications of influenza are not captured by this study design
• Selection bias due to the inclusion of subjects for exacerbation of chronic 
pulmonary conditions that are not caused by acute respiratory infection is a 
potential problem of inpatient TND studies which requires careful 
consideration.
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Table 1
Parameter descriptions and symbols with default values. The index 0/1 denotes parameter values for 
individuals without chronic cardiopulmonary (CP) conditions and CP individuals, respectively.
Parameter Symbol Baseline value
Total population size Npop 1E + 06
Target no.of cases - 500
Target no.of controls - 1000
Duration of study (days) τ 150
Prevalence of CP status η 0.2
Vaccination uptake (non-CP) ν0 0.4
Vaccination uptake (CP) ν1 0.8
Vaccine efficacy against infection φ 0.6
Proportion of influenza hospitalizations prevented by vaccine, given infection ι 0
Incidence constant (maximum daily influenza incidence rate per 1000 per day) λ0 4.0
Incidence rate of influenza infection at time t λI(t) λosint/τπ
Incidence rate of non-influenza infection at time t λNI(t) λocost/τπ + abs(min(costv/eτrπb, a rt; ∈; (;0;,;τ;))
Incidence rate of non-acute respiratory infection (ARI) events (non-CP) λCP0 Mean(λNI(t))/10
Incidence rate of non-ARI events (CP) λCP1 Mean(λNI(t))
Testing probability of inpatients σ 0.5
Test sensitivity α 1.0
Test sensitivity reduction by vaccination ξ 0.0
Influenza test specificity ε 1.0
Vaccine status assessment sensitivity ψ 1.0
Vaccine status assessment specificity ω 1.0
CP status assessment sensitivity ζ 1.0
CP status assessment specificity θ 1.0
Probability of hosp.resulting from influenza (non-CP) γI0 0.01
Probability of hospitalization (hosp) resulting from influenza (CP) γI1 0.05
Probability of hosp.with non-influenza ARI (non-CP) γNI0 0.01
Probability of hosp.with non-influenza ARI (CP) γNI1 0.05
Probability of hosp.with non-ARI events (non-CP) γCP0 0.02
Probability of hosp.with non-ARI events (CP) γCP1 0.1
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Table 2
The comparison of vaccine effectiveness (VE) estimates from simulated inpatient test-negative design (TND) 
studies with the actual vaccine protection from influenza hospitalization (hosp.) in simulated cohort studies 
(see text) for different values of the proportion of influenza hospitalization that is prevented by vaccination 
(l)in ‘vaccine failures’. VE against infections is 60% for all scenarios. For each value l, 1 000 simulations were 
performed
ιa VE against hosp.b Cohort VE against hosp. (%) Inpatient TND VE (%) VE difference (% points)
0.0 60 60 (54.4, 65) 60.1 (48.5, 69)d −0.1 (−9.1, 10.8)
0.1 64 64 (58.9, 68.6) 64.1 (53.8, 72.1) −0.1 (−8.1, 9.7)
0.2 68 68 (63.1, 72.2)    68 (59, 75.1) −0.1 (−7.2, 8.5)
0.3 72 72 (67.7, 75.8) 72.2 (64.3, 78.4) −0.2 (−6.4, 7.3)
0.4 76 76 (72.2, 79.5) 76.1 (69, 81.5) −0.1 (−5.6, 6.5)
0.5 80 80 (76.6, 83) 80.1 (74.3, 84.8) −0.1 (−4.7, 5.4)
0.6 84 84 (81, 86.6) 84.1 (79.2, 87.9) −0.1 (−4, 4.4)
0.7 88 88 (85.5, 90.1)    88 (84.1, 91.2)      0 (−3.1, 3.5)
0.8 92 92 (90.1, 93.6) 92.1 (89.2, 94.3) −0.1 (−2.2, 2.5)




Influenza hosp. prevented by vaccination, given infection.
b
Calculated as φ* = 1 − (1 − ι) (1 − φ).
c
Median (2.5th, 97.5th percentile).
d
Adjusted for chronic cardiopulmonary (CP) status.













Foppa et al. Page 14
Table 3
Empirical bias distribution of crude vaccine effectiveness (VE) estimates and VE estimates adjusted for 
chronic cardiopulmonary (CP) status. These estimates were obtained from simulated inpatient test-negative 
design (TND) studies, using default parameter values in 10 000 simulations




Crude 10.66 (3.24, 16.68)a
Restricted to subjects
without CP




CP-adjusted −0.08 (−11.09, 8.81)
Heterogeneity
within CP = 1
(see text)
Crude 13.23 (6.28, 18.89)
Restricted to subjects
without CP
  0.17 (−32.77, 18.48)
Restricted to subjects
with CP
       8 (−1.87, 15.93)
CP-adjusted,
imperfectly
  6.78 (−2.55, 14.32)
a
Median (2.5th, 97.5th percentile).
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